HCM
BNTX icon

Highlander Capital Management’s BioNTech BNTX Stock Holding History

Highlander Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-300
Closed -$77K – 612
2021
Q4 		$77K Hold
300
– – 0.04% 236
2021
Q3 		$82K Sell
300
-200
-40% -$63.6K 0.04% 228
2021
Q2 		$112K Hold
500
– – 0.06% 211
2021
Q1 		$55K Buy
+500
New +$53.1K 0.03% 273
2020
Q4 		– Sell
-500
Closed -$35K – 608
2020
Q3 		$35K Buy
+500
New +$35.9K 0.02% 328

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Highlander Capital Management's BNTX Position: Q1 2022 in Review

Highlander Capital Management sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 300 shares — an estimated $77K sold.

Highlander Capital Management first reported a position in BNTX in Q3 2020 and held it in 5 quarters. The position peaked at $112K in Q2 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

  • Highlander Capital Management reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
  • Highlander Capital Management sold 300 BioNTech shares in Q1 2022, an estimated $77K.
  • Highlander Capital Management first reported a position in BioNTech in Q3 2020 and held it in 5 quarters.
  • Highlander Capital Management's BioNTech position peaked at $112K in Q2 2021.
  • 287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Highlander Capital Management's 13F filing for Q1 2022, filed 9 May 2022.